Nanobiotix Announces the Publication of its 2025 Annual Results

On March 31, 2026, after the close of the U.S. market, Nanobiotix will release its financial and operational results for fiscal year 2025. The company, which specializes in innovative nanoparticle-based therapeutic approaches, will hold a conference call and webcast the following day. This event, scheduled for April 1, 2026, at 2:00 p.m. CEST, will be led by Laurent Levy, Chairman of the Executive Board, and Bart Van Rhijn, Chief Financial Officer. They will briefly discuss the annual results and provide an overview of the past year's operational activities before answering questions from participants. Investors can submit their questions in advance by email.